Lilly to buy Loxo Oncology for about Sh800 billion in cancer genetics bet

Lilly to buy Loxo Oncology for about $8 billion in cancer genetics bet. [Courtesy]

Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash, buying into a portfolio of targeted medicines to treat cancers caused by rare gene mutations.

The offer of $235 per share in cash represents a premium of about 68 percent to Loxo’s Friday close. Loxo’s shares surged 32.8 percent to $185.70 in light trading before the bell, while those of Lilly dropped 2.7 percent to $111.60.

Last year, U.S. regulators approved Loxo’s first commercial medicine, Vitrakvi, which was shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation. The drug is sold in partnership with Bayer AG.

Loxo Oncology is developing a pipeline of targeted medicines focused on such cancers that can be detected by genomic testing.

Deutsche Bank is Lilly’s financial adviser and Weil, Gotshal & Manges LLP is its legal adviser. Goldman Sachs & Co LLC is the financial adviser, while Fenwick & West LLP is legal adviser to Loxo.

By Philip Mwakio 40 mins ago
Business
Coast hoteliers anxious as agency issues alert over rising sea level
Opinion
Premium Sugar cane farmers should now move to dairy, avocado farming
Business
No reprieve for bank in Sh33 billion case with Manchester Outfitters
Business
Tourism players differ over KWS plan to hire out national park sites